

SUPPORTING INFORMATION

Synthesis of enantiomerically pure ring-substituted L-pyridylalanines by biocatalytic hydroamination

Syed T. Ahmed, Fabio Parmeggiani, Nicholas J. Weise, Sabine L. Flitsch, Nicholas J. Turner*

School of Chemistry, The University of Manchester, Manchester Institute of Biotechnology (MIB), 131 Princess Street, M1 7DN, Manchester, United Kingdom

<u>Table of Contents</u>	<u>Page</u>
General methods	S2
Chemicals and enzymes.....	S2
NMR spectroscopy	S2
High-resolution mass spectrometry	S2
Molecular biology protocols.....	S3
Strains and plasmids	S3
Transformation into competent cells	S3
Biocatalyst production	S3
NMR time-course experiment.....	S4
Telescopic synthesis of L- 5a-f	S10
HPLC methods.....	S13
Conversion	S13
Enantiomeric excess	S13
Chiral HPLC chromatograms.....	S15
Synthetic procedures and biotransformation protocols	S24
Characterisation data of compounds 2a-l , 3a-l , 4a-f and 5a-e	S26
¹ H NMR, ¹³ C NMR and HRMS spectra.....	S35
References	S107

* Corresponding author. E-mail address: nicholas.turner@manchester.ac.uk

General methods

Chemicals and enzymes

Analytical grade reagents, solvents and heteroaromatic aldehydes were obtained from Sigma-Aldrich, Alfa-Aesar or Fluorochem and have been used without further purification. D-amino acid oxidase (DAAO) from porcine kidney and L-amino acid oxidase (LAAO) from *Crotalus adamanteus* were purchased from Sigma-Aldrich.

NMR spectroscopy

^1H and ^{13}C NMR spectra were recorded on a Bruker Avance 400 spectrometer (400 MHz) at 298 K without additional internal standard. Chemical shifts are reported as δ in parts per million (ppm) and are calibrated against residual solvent signal. A water suppression method was used to obtain the ^1H NMR spectra in water, with D_2O as the residual solvent peak (^1H NMR: D_2O = 4.79 ppm). ^1H NMR data were analysed on MestreNova and are reported as follows: chemical shift (ppm), multiplicity (s = singlet, d = doublet, dd = doublet of doublets, t = triplet, m = multiplet), coupling constants (Hz) and integration. ^{13}C NMR data for compounds **4b**, **4d** and **5e** were recorded on a Bruker Avance III 500 spectrometer (500 MHz).

High-resolution mass spectrometry

HRMS analysis was performed using a Waters LCT time-of-flight mass spectrometer connected to a Waters Alliance LC (Waters, Milford, MA, USA). For halogen-substituted compounds, only the ion containing the most abundant isotope was reported (^{79}Br and ^{35}Cl).

Molecular biology protocols

Strains and plasmids

E. coli BL21(DE3) was used as an expression host for protein production. The pET16b-AvPAL plasmid containing *Anabaena variabilis* (codon-optimised for *E. coli*) was obtained as described previously.¹

Standard LB medium was used for cell growth, with the addition of ampicillin (Amp) to a final concentration of 100 µg mL⁻¹. Solid media were prepared by addition of agar (1.5% w/v) to liquid media.

Transformation into competent cells

Competent cells (50 µL aliquot) were thawed on ice for 15 min, transferred to a pre-chilled tube containing plasmid DNA (20-50 ng). The tubes were gently flicked for mixing, incubated in ice for 30 min, heat-shocked at 42°C for 30 s and transferred back to ice for 5 min. SOC medium (900 µL) was added to the tube under sterile conditions and incubated at 37°C, 250 rpm for 1 h. The culture was then concentrated to 100 µL (by centrifugation and resuspension) and spread across an LB plate containing ampicillin, under sterile condition. Plates were incubated overnight at 37°C and stored at 4°C.


Biocatalyst production

A single colony of *E. coli* BL21(DE3) carrying the pET16b-AvPAL plasmid was used to inoculate LB medium (8 mL) supplemented with ampicillin, which was grown overnight at 37°C and 220 rpm. The starter culture was used to inoculate LB-based auto-induction medium² (800 mL, Formedium) containing ampicillin and glycerol (0.5% v/v) which was incubated at 18°C and 250 rpm for 4 days. The cells (approximately 5 g) were harvested by centrifugation (5,000 rpm, 20 min, 4°C) and flash frozen in liquid nitrogen. Frozen cells were lyophilized under high vacuum overnight to yield the powdered formulation of the biocatalyst which was stored at -20°C.


NMR time-course experiment

Conversion for compounds **3g-l** were obtained by ^1H NMR, monitoring the appearance of the ABX system corresponding to the aliphatic portion of the amino acid and the disappearance of the acrylic acid doublets. A sample of the crude biotransformation mixture (600 μL) was added to D_2O (200 μL), thoroughly mixed and centrifuged to remove whole cell components and insoluble solids. The supernatant was then analysed by NMR with suppression of the residual water signal. Representative spectra are shown in the following.


3h




3i




3j




3k




3l




5a




5b




5c




5d



5e





Telescopic synthesis of L-5a-f




Prod.	Time (h)	Conv. (%)	ee (%)	Isol. yield (%)
5a	22	>99	>99	40
5b	4	88	>99	35
5c	4	95	>99	54
5d	4	80	>99	44
5e	22	93	>99	37
5f	30	<5	—	—

Unsuccessful biotransformations/syntheses



(E)-3-(6-methoxypyridin-3-yl) acrylic acid (2m) was synthesized and tested with AvPAL. No conversion was observed after 30 h incubation.



Also, the synthesis and isolation of (E)-3-(2-bromopyridin-3-yl)acrylic acid (2n) was unsuccessful, with no trace of the acrylic acid doublets present whilst following the reaction by NMR. The reaction mixture turned black (as opposed to being colorless to pale yellow) yielding a black/grey solid.



(E)-3-(isoquinolin-4-yl)acrylic acid (4f) was synthesized successfully and tested with AvPAL yielding no conversion after 30 h incubation.



HPLC methods

Conversion

The conversion of compounds **2a-f** to **3a-f** was measured on a non-chiral reverse-phase Zorbax C-18 Extend column (50 mm x 4.5 μ m, Agilent). Mobile phase aq. NH_4OH 0.1 M pH 10 / MeOH 90:10 (12 min), flow rate 1 mL min^{-1} , temperature 40°C, detection wavelength 210 nm (retention time are reported below).

	Retention time (t_R)	
	[min]	
	3	2
a	2.30	5.00
b	2.37	5.35
c	2.65	7.01
d	3.17	8.53
e	1.80	3.40
f	1.90	3.16

Enantiomeric excess

The optical purity of amino acid products **3a-j** and **5a-e** was measured on a reverse-phase Crownpak CR(+) column (150 mm x 4 mm x 3.5 μ m, Daicel). Mobile phase aq. HClO_4 1.14% w/v / MeOH 96:4, flow rate 1.0 mL min^{-1} , temperature 40°C, detection wavelength 210 nm. The optical purity of amino acid products **3k-l** was measured on a reverse-phase Chirobiotic T column (250 mm x 46 mm x 5 μ M, Supelco). Mobile phase H_2O /MeOH 60:40, flow rate 0.8 mL min^{-1} , temperature 40°C, detection wavelength 210 nm (retention times are reported below).


	Retention time (t_R)	
	[min]	
	D-3	L-3
a	5.45	7.20
b	3.58	4.28
c	7.45	9.76
d	7.57	9.06
e	4.01	5.56
f	1.93	2.14
g	3.23	6.79
h	1.84	2.06
i	3.35	4.55
j	6.94	9.21
k	— ^a	8.65
l	6.16	5.59

^aD-**3k** could not be produced with the method described below.



	Retention time (t_R)	
	[min]	
	D-5	L-5
a	2.17	2.54
b	19.80	26.25
c	16.15	22.80
d	14.00	18.50
e	— ^a	2.10



^aD-5e could not be produced with the method described below.



Compounds **3a**, **g**, **k**, **l** gave >99% L-enantiomer in all cases. In order to verify the separation capability of the column employed, a deracemisation was performed to produce a small but measurable amount of the D-enantiomer. This was done with a chemo-enzymatic cascade identical to the one described in the paper for the chiral polishing of the L-enantiomer (as shown in the scheme below), but using in this case L-amino acid oxidase (LAAO) instead of DAAO.







Chiral HPLC chromatograms


























Synthetic procedures and biotransformation protocols

Knoevenegel-Doebner synthesis of acrylic acids 2a-l and 4a-f

The suitable aldehyde (1 mmol) and malonic acid (3 mmol) were added to DMSO (1 mL). The mixture (final conc. 1 M aldehyde) was stirred until complete dissolution of the starting materials. Piperidine (2 mol%) was added, followed by heating at 100°C for 16 h. The mixture was cooled to room temperature and quenched with distilled water (5 mL) resulting in the precipitation of the acrylic acid. The solid was centrifuged and the water removed by decanting. The acrylic acid was washed 3 times by re-suspending in distilled water (5 mL) with decanting the liquid each time. Methanol (10 mL) was added to transfer the solid to a round-bottomed flask, followed by concentrating the sample *in vacuo* to give the title compound as a white solid.

Telescopic synthesis of amino acids 3a-l and 5a-f

The crude condensation mixture (500 μ L) was added to a saturated solution of ammonium carbamate (9.5 mL) to give a final concentration of 50 mM acrylic acid. Lyophilized cells producing AvPAL (250 mg, 25 mg mL⁻¹) were added and the mixture was shaken until complete resuspension of the biocatalyst. The suspension was incubated at 37°C, 180 rpm for 2-30 h. Once the biotransformation reached full conversion (by HPLC and/or ¹H NMR), the mixture was centrifuged (4000 rpm, 10 min, 4°C) and the supernatant collected for purification. To follow the reaction by HPLC analysis, a sample of the biotransformation mixture (50 μ L) was added to MeOH (450 μ L), thoroughly mixed and centrifuged (13000 rpm, 1 min, 4°C). The supernatant was transferred to a filter vial and used directly for analysis.

Purification of amino acids 3a-l and 5a-f


Supernatant from the reaction mixture was acidified to pH < 2.0 by addition of aqueous H₂SO₄ (10% w/v) and centrifuged (4000 rpm, 10 min, 4°C) to remove cells and insoluble components. Dowex[®] 50WX8 hydrogen form (2.5 g) was washed with deionised water (50 mL) and aqueous H₂SO₄ (25 mL, 10% w/v). The acidified supernatant from the biotransformation was loaded onto the resin (1 mL min⁻¹). The resin was washed repeatedly with deionised water (until pH ~ 7) and the product was eluted with aqueous NH₄OH (30 mL, 10% w/v). Fractions containing the product were pooled and evaporated in a centrifugal evaporator, to afford amino acids L-**3a-l**.

Deracemisation cascade of compounds 3a-l using DAAO

Amino acid **3a-l** (10 mM) and borane-ammonia complex (50 mM) were dissolved in phosphate buffer (2 mL, 100 mM, pH 8.0). DAAO (1 mg mL⁻¹) was added to start the reaction and the mixture was incubated at 37°C for 1-3 h. To monitor the reaction, samples (200 uL) were taken at regular intervals, diluted with methanol (200 uL), centrifuged (13000 rpm, 1 min, 4°C) and the supernatant analysed by HPLC on a chiral stationary phase.³ The same method (using LAAO instead of DAAO) was used to produce HPLC standards of the D-enantiomers of compounds that were obtained enantiomerically pure from the biotransformations.

Characterisation data of compounds 2a-l, 3a-l, 4a-f and 5a-e


(E)-3-(6-bromopyridin-3-yl) acrylic acid (2a)



White solid (91 mg, 40%); $^1\text{H NMR}$ (400 MHz, $\text{D}_2\text{O}+\text{NaOH}$) δ 8.22 (s, 1H), 7.72 (d, $J = 8$ Hz, 1H), 7.47 (d, $J = 8$ Hz, 1H), 7.14 (d, $J = 16$ Hz, 1H), 6.45 (d, $J = 16$ Hz, 1H); $^{13}\text{C NMR}$ (100 MHz, $\text{D}_2\text{O}+\text{NaOH}$) δ 174.58, 148.72, 140.85, 137.38, 135.24, 130.86, 128.48, 127.34;

HRMS-ESI (m/z) $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_8\text{H}_6\text{BrNO}_2$: 227.9655; found, 227.9652.


(E)-3-(5-bromopyridin-3-yl) acrylic acid (2b)



White solid (50 mg, 22%); $^1\text{H NMR}$ (400 MHz, $\text{D}_2\text{O}+\text{NaOH}$) δ 8.37 (s, 2H), 8.00 (s, 1H), 7.10 (d, $J = 16$ Hz, 1H), 6.43 (d, $J = 16$ Hz, 1H); $^{13}\text{C NMR}$ (100 MHz, $\text{D}_2\text{O}+\text{NaOH}$) δ 174.32, 149.56, 146.28,

137.22, 134.87, 133.00, 128.04, 120.68; **HRMS-ESI** (m/z) $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_8\text{H}_6\text{BrNO}_2$: 227.9655; found, 227.9652.


(E)-3-(6-bromopyridin-2-yl) acrylic acid (2c)



White solid (52 mg, 23%); $^1\text{H NMR}$ (400 MHz, $\text{D}_2\text{O}+\text{NaOH}$) δ 7.58 (t, $J = 8$ Hz, 1H) 7.40-7.45 (m, 2H), 7.03 (d, $J = 16$ Hz, 1H), 6.56 (d, $J = 16$ Hz, 1H); $^{13}\text{C NMR}$ (100 MHz, $\text{D}_2\text{O}+\text{NaOH}$) δ 174.32, 154.84, 141.10, 104.19, 137.21, 129.77, 128.21, 122.23; **HRMS-ESI** (m/z) $[\text{M}+\text{H}]^+$ Calcd

for $\text{C}_8\text{H}_6\text{BrNO}_2$: 227.9655; found, 227.9649.


(E)-3-(5-bromopyridin-2-yl) acrylic acid (2d)



Pale yellow solid (59 mg, 26%); $^1\text{H NMR}$ (400 MHz, $\text{D}_2\text{O}+\text{NaOH}$) δ 8.46 (s, 1H), 7.89 (d, $J = 8$ Hz, 1H), 7.42 (d, $J = 8$ Hz, 2H), 7.16 (d, $J = 16$ Hz, 1H), 6.62 (d, $J = 16$ Hz, 1H); $^{13}\text{C NMR}$ (100 MHz, $\text{D}_2\text{O}+\text{NaOH}$) δ 174.62, 151.94, 150.01, 140.48, 137.63, 129.22,


124.53, 120.39; **HRMS-ESI** (m/z) $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_8\text{H}_6\text{BrNO}_2$: 227.9655; found, 227.9652.

(E)-3-(2-bromopyridin-4-yl) acrylic acid (2e)




White solid (224 mg, 99%); $^1\text{H NMR}$ (400 MHz, $\text{D}_2\text{O}+\text{NaOH}$) δ 8.11 (d, $J = 8$ Hz, 1H), 7.53 (s, 1H), 7.33 (d, $J = 4$ Hz, 1H), 7.04 (s, $J = 16$ Hz, 1H), 6.55 (d, $J = 16$ Hz, 1H); $^{13}\text{C NMR}$ (100 MHz, $\text{D}_2\text{O}+\text{NaOH}$) δ 174.00, 149.65, 146.60, 141.28, 135.64, 130.70, 126.17, 121.37; **HRMS-ESI** (m/z) $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_8\text{H}_6\text{BrNO}_2$: 227.9655; found, 227.9650.

(E)-3-(3-bromopyridin-4-yl) acrylic acid (2f)




White solid (158 mg, 70%); $^1\text{H NMR}$ (400 MHz, $\text{D}_2\text{O}+\text{NaOH}$) δ 8.50 (s, 1H), 8.25 (d, $J = 4$ Hz, 1H), 7.45 (d, $J = 4$ Hz, 1H), 7.37 (d, $J = 16$ Hz, 1H), 6.51 (d, $J = 16$ Hz, 1H); $^{13}\text{C NMR}$ (100 MHz, $\text{D}_2\text{O}+\text{NaOH}$) δ 173.85, 151.31, 147.28, 143.38, 135.48, 131.38, 121.85, 121.78; **HRMS-ESI** (m/z) $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_8\text{H}_6\text{BrNO}_2$: 227.9655; found, 227.9651.

(E)-3-(6-chloropyridin-3-yl) acrylic acid (2g)




White solid (92 mg, 50%); $^1\text{H NMR}$ (400 MHz, $\text{D}_2\text{O}+\text{NaOH}$) δ 8.36 (s, 1H), 7.94 (d, $J = 4$ Hz, 1H), 7.41 (d, $J = 4$ Hz, 1H), 7.24 (d, $J = 16$ Hz, 1H), 6.49 (d, $J = 16$ Hz, 1H); $^{13}\text{C NMR}$ (100 MHz, $\text{D}_2\text{O}+\text{NaOH}$) δ 174.73, 150.37, 148.43, 137.90, 135.35, 130.68, 127.19, 124.72; **HRMS-ESI** (m/z) $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_8\text{H}_6\text{ClNO}_2$: 184.0160; found, 184.0158.

(E)-3-(3-chloropyridin-4-yl) acrylic acid (2h)




White solid (81 mg, 44%); $^1\text{H NMR}$ (400 MHz, $\text{D}_2\text{O}+\text{NaOH}$) δ 8.39 (s, 1H), 8.25 (d, $J = 8$ Hz, 1H), 7.49 (d, $J = 8$ Hz, 1H), 7.44 (d, $J = 16$ Hz, 1H), 6.55 (d, $J = 16$ Hz, 1H); $^{13}\text{C NMR}$ (100 MHz, $\text{D}_2\text{O}+\text{NaOH}$) δ 173.93, 148.84, 146.77, 141.61, 132.89, 131.33, 131.04, 121.43; **HRMS-ESI** (m/z) $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_8\text{H}_6\text{ClNO}_2$: 184.0160; found, 184.0158.

(E)-3-(2-chloropyridin-4-yl) acrylic acid (2i)




White solid (79 mg, 43%); $^1\text{H NMR}$ (400 MHz, $\text{D}_2\text{O}+\text{NaOH}$) δ 8.19 (s, J = 8 Hz, 1H), 7.47 (s, 1H), 7.37 (d, J = 8 Hz, 1H), 7.12 (d, J = 16 Hz, 1H), 6.60 (d, J = 16 Hz, 1H); $^{13}\text{C NMR}$ (100 MHz, $\text{D}_2\text{O}+\text{NaOH}$) δ 174.10, 150.80, 149.21, 147.04, 135.80, 130.61, 122.49, 121.05; **HRMS-ESI** (m/z) [$\text{M}+\text{H}$] $^+$ Calcd for $\text{C}_8\text{H}_6\text{ClNO}_2$: 184.0160; found, 184.0157.

(E)-3-(2,5-dichloropyridin-4-yl) acrylic acid (2j)




White crystals (69 mg, 32%); $^1\text{H NMR}$ (400 MHz, $\text{D}_2\text{O}+\text{NaOH}$) δ 8.26 (s, 1H), 7.64 (s, 1H), 7.41 (d, J = 16 Hz, 1H), 6.60 (d, J = 16 Hz, 1H); $^{13}\text{C NMR}$ (100 MHz, $\text{D}_2\text{O}+\text{NaOH}$) δ 173.59, 148.84, 148.78, 144.42, 132.56, 131.92, 130.05, 121.71; **HRMS-ESI** (m/z) [$\text{M}+\text{H}$] $^+$ Calcd for $\text{C}_8\text{H}_5\text{Cl}_2\text{NO}_2$: 217.9770; found, 217.9793

(E)-3-(2-methoxypyridin-4-yl) acrylic acid (2k)




White solid (72 mg, 40%); $^1\text{H NMR}$ (400 MHz, $\text{D}_2\text{O}+\text{NaOH}$) δ 8.00 (s, 1H), 7.90 (d, J = 8 Hz, 1H), 7.27 (d, J = 16 Hz, 1H), 7.20 (d, J = 4 Hz, 1H), 6.45 (d, J = 16 Hz, 1H), 3.79 (s, 3H); $^{13}\text{C NMR}$ (100 MHz, $\text{D}_2\text{O}+\text{NaOH}$) δ 174.68, 152.86, 141.39, 133.24, 132.18, 132.86, 129.53, 121.51, 56.19; **HRMS-ESI** (m/z) [$\text{M}+\text{H}$] $^+$ Calcd for $\text{C}_9\text{H}_9\text{NO}_3$: 180.0655; found, 180.0663.

(E)-3-(3-methoxypyridin-4-yl) acrylic acid (2l)




White solid (91 mg, 51%); $^1\text{H NMR}$ (400 MHz, $\text{D}_2\text{O}+\text{NaOH}$) δ 7.86 (d, J = 4 Hz, 1H), 7.05 (d, J = 16 Hz, 1H), 6.96 (d, J = 4 Hz, 1H), 6.98 (s, 1H), 6.48 (d, J = 16 Hz, 1H), 3.77 (s, 3H); $^{13}\text{C NMR}$ (100 MHz, $\text{D}_2\text{O}+\text{NaOH}$) δ 173.80, 163.47, 146.10, 145.76, 136.45, 128.58, 114.74, 107.83, 53.42; **HRMS-ESI** (m/z) [$\text{M}+\text{H}$] $^+$ Calcd for $\text{C}_9\text{H}_9\text{NO}_3$: 180.0655; found, 180.0663.

(E)-3-(6-methoxypyridin-3-yl) acrylic acid (2m)




White solid (86 mg, 48%); $^1\text{H NMR}$ (400 MHz, $\text{D}_2\text{O}+\text{NaOH}$) δ 8.03 (s, 1H), 7.85 (d, $J = 8$ Hz, 1H), 7.19 (d, $J = 16$ Hz, 1H), 6.76 (d, $J = 12$ Hz, 1H), 6.32 (d, $J = 16$ Hz, 1H), 3.83 (s, 3H); $^{13}\text{C NMR}$ (100 MHz, $\text{D}_2\text{O}+\text{NaOH}$) δ 175.30, 164.11, 146.52, 137.75, 136.66, 125.10, 123.73, 110.60; **HRMS-ESI** (m/z) $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_9\text{H}_9\text{NO}_3$: 180.0655; found, 180.0654.

(S)-2-amino-3-(6-bromopyridin-3-yl) propanoic acid (3a)




White solid (62 mg, 51%); $^1\text{H NMR}$ (400 MHz, $\text{D}_2\text{O}+\text{NaOH}$) δ 8.12 (s, 1H), 7.51-7.58 (m, 2H), 3.48 (t, $J = 8$ Hz, 1H), 2.88-2.93 (dd, $J = 16, 8$ Hz, 1H), 2.80-2.85 (dd, $J = 12, 8$ Hz, 1H); $^{13}\text{C NMR}$ (100 MHz, $\text{D}_2\text{O}+\text{NaOH}$) δ 181.18, 149.98, 140.79, 138.82, 133.75, 128.18, 56.90, 37.02; **HRMS-ESI** (m/z) $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_8\text{H}_9\text{BrN}_2\text{O}_2$: 244.9920; found, 244.9785.

(S)-2-amino-3-(5-bromopyridin-3-yl) propanoic acid (3b)




White solid (57 mg, 47%); $^1\text{H NMR}$ (400 MHz, $\text{D}_2\text{O}+\text{NaOH}$) δ 8.36 (s, 1H), 8.18 (s, 1H), 7.78 (s, 1H), 3.35-3.38 (dd, $J = 8, 4$ Hz, 1H), 2.80-2.85 (dd, $J = 16, 8$ Hz, 1H), 2.69-2.75 (dd, $J = 16, 8$ Hz, 1H); $^{13}\text{C NMR}$ (100 MHz, $\text{D}_2\text{O}+\text{NaOH}$) δ 181.43, 147.90, 147.65, 140.50, 136.50, 120.30, 57.07, 37.56; **HRMS-ESI** (m/z) $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_8\text{H}_9\text{BrN}_2\text{O}_2$: 244.9920; found, 244.9923.

(S)-2-amino-3-(6-bromopyridin-2-yl) propanoic acid (3c)




White solid (64 mg, 53%); $^1\text{H NMR}$ (400 MHz, $\text{D}_2\text{O}+\text{NaOH}$) δ 7.51 (t, $J = 8$ Hz, 1H), 7.35 (d, $J = 8$ Hz, 1H), 7.16 (d, $J = 8$ Hz), 3.42-3.46 (dd, $J = 8, 8$ Hz, 1H), 2.93-2.98 (dd, $J = 16, 8$ Hz, 1H), 2.69-2.75 (dd, $J = 16, 8$ Hz, 1H); $^{13}\text{C NMR}$ (100 MHz, $\text{D}_2\text{O}+\text{NaOH}$) δ 181.60, 159.94, 140.37, 140.18, 126.40, 123.43, 56.79, 42.37; **HRMS-ESI** (m/z) $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_8\text{H}_9\text{BrN}_2\text{O}_2$: 244.9920; found, 244.9901.

(S)-2-amino-3-(5-bromopyridin-2-yl) propanoic acid (3d)




White solid (53 mg, 44%); $^1\text{H NMR}$ (400 MHz, $\text{D}_2\text{O}+\text{NaOH}$) δ 8.50 (s, 1H), 7.90 (d, $J = 8$ Hz, 1H), 7.21 (d, $J = 8$ Hz, 1H), 3.53-3.57 (dd, $J = 8, 8$ Hz, 1H), 3.03-3.08 (dd, $J = 16, 8$ Hz, 1H), 2.83-2.88 (dd, $J = 12, 8$ Hz, 1H); $^{13}\text{C NMR}$ (100 MHz, $\text{D}_2\text{O}+\text{NaOH}$) δ 181.73, 156.76, 149.33, 140.31, 125.81, 118.40, 56.74, 42.05; **HRMS-ESI** (m/z) $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_8\text{H}_9\text{BrN}_2\text{O}_2$: 244.9920; found, 244.9871.

(S)-2-amino-3-(2-bromopyridin-4-yl) propanoic acid (3e)




White solid (63 mg, 52%); $^1\text{H NMR}$ (400 MHz, $\text{D}_2\text{O}+\text{NaOH}$) δ 8.09 (d, $J = 8$ Hz, 1H), 7.40 (s, 1H), 7.17 (d, $J = 8$ Hz, 1H), 3.39-3.42 (dd, $J = 8, 4$ Hz, 1H), 2.69-2.75 (dd, $J = 16, 8$ Hz, 1H); $^{13}\text{C NMR}$ (100 MHz, $\text{D}_2\text{O}+\text{NaOH}$) δ 181.27, 152.20, 149.26, 140.80, 129.06, 124.42, 56.73, 39.94; **HRMS-ESI** (m/z) $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_8\text{H}_9\text{BrN}_2\text{O}_2$: 244.9920; found, 246.9985.

(S)-2-amino-3-(3-bromopyridin-4-yl) propanoic acid (3f)




White solid (58 mg, 48%); $^1\text{H NMR}$ (400 MHz, $\text{D}_2\text{O}+\text{NaOH}$) δ 8.57 (s, 1H), 8.30 (d, $J = 4$ Hz, 1H), 7.29 (d, $J = 4$ Hz, 1H), 3.55 (t, $J = 8$ Hz, 1H), 3.04-3.09 (dd, $J = 16, 8$ Hz, 1H), 2.90-2.95 (dd, $J = 12, 8$ Hz, 1H); $^{13}\text{C NMR}$ (100 MHz, $\text{D}_2\text{O}+\text{NaOH}$) δ 181.46, 150.74, 148.41, 147.14, 126.64, 123.20, 55.97, 40.39; **HRMS-ESI** (m/z) $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_8\text{H}_9\text{BrN}_2\text{O}_2$: 244.9920; found, 244.9871.

(S)-2-amino-3-(6-chloropyridin-3-yl) propanoic acid (3g)




White solid (45mg, 45%); $^1\text{H NMR}$ (400 MHz, $\text{D}_2\text{O}+\text{NaOH}$) δ 8.15 (s, 1H), 7.67 (d, $J = 8$ Hz, 1H), 7.40 (d, $J = 8$ Hz, 1H), 3.46 (t, $J = 8$ Hz, 1H), 2.89-2.94 (dd, $J = 16, 8$ Hz, 1H), 2.81-2.87 (dd, $J = 16, 8$ Hz, 1H); $^{13}\text{C NMR}$ (100 MHz, $\text{D}_2\text{O}+\text{NaOH}$) δ 181.12, 149.37, 148.52, 141.04, 133.31, 124.38, 56.95, 36.90; **HRMS-ESI** (m/z) $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_8\text{H}_9\text{ClN}_2\text{O}_2$: 201.0425; found, 201.0422.

(S)-2-amino-3-(3-chloropyridin-4-yl) propanoic acid (3h)




White solid (40 mg, 40%); $^1\text{H NMR}$ (400 MHz, $\text{D}_2\text{O}+\text{NaOH}$) δ 8.36 (s, 1H), 8.19 (d, $J = 4$ Hz, 1H), 7.21 (d, $J = 4$ Hz, 1H), 3.46 (t, $J = 8$ Hz, 1H), 2.96-3.01 (dd, $J = 12, 8$ Hz, 1H), 2.82-2.88 (dd, $J = 16, 8$ Hz, 1H); $^{13}\text{C NMR}$ (100 MHz, $\text{D}_2\text{O}+\text{NaOH}$) δ 181.46, 148.13, 146.60, 132.47, 126.42, 55.87, 37.93; **HRMS-ESI** (m/z) $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_8\text{H}_9\text{ClN}_2\text{O}_2$: 201.0425; found, 201.0421.

(S)-2-amino-3-(2-chloropyridin-4-yl) propanoic acid (3i)




White solid (60 mg, 50%); $^1\text{H NMR}$ (400 MHz, $\text{D}_2\text{O}+\text{NaOH}$) δ 8.09 (d, $J = 4$ Hz, 1H), 7.23 (s, 1H), 7.12 (d, $J = 4$ Hz, 1H), 3.42 (t, $J = 8$ Hz, 1H), 2.84-2.89 (dd, $J = 16, 8$ Hz, 1H), 2.71-2.77 (dd, $J = 16, 8$ Hz, 1H); $^{13}\text{C NMR}$ (100 MHz, $\text{D}_2\text{O}+\text{NaOH}$) δ 181.07, 152.36, 150.23, 148.73, 125.24, 124.04, 56.66, 39.86; **HRMS-ESI** (m/z) $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_8\text{H}_9\text{ClN}_2\text{O}_2$: 201.0425; found, 201.0421.

(S)-2-amino-3-(2,5-dichloropyridin-4-yl) propanoic acid (3j)




White solid (32 mg, 32%); $^1\text{H NMR}$ (400 MHz, $\text{D}_2\text{O}+\text{NaOH}$) δ 8.18 (s, 0.5H), 7.29 (s, 1H), 3.44 (t, $J = 8$ Hz, 1H), 2.94-2.96 (dd, $J = 16, 8$ Hz, 1H), 2.78-2.84 (dd, $J = 16, 8$ Hz, 1H); $^{13}\text{C NMR}$ (100 MHz, $\text{D}_2\text{O}+\text{NaOH}$) δ 181.17, 149.66, 148.37, 148.07, 131.53, 126.41, 55.71, 37.99; **HRMS-ESI** (m/z) $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_8\text{H}_8\text{Cl}_2\text{N}_2\text{O}_2$: 235.0036; found, 235.0063.

(S)-2-amino-3-(2-methoxypyridin-4-yl) propanoic acid (3k)




White solid (45 mg, 46%); $^1\text{H NMR}$ (400 MHz, $\text{D}_2\text{O}+\text{NaOH}$) δ 8.03 (s, 1H), 7.93 (d, $J = 8$ Hz, 1H), 7.07 (d, $J = 4$ Hz, 1H), 3.78 (s, 3H), 3.43 (t, $J = 8$ Hz, 1H), 2.84-2.89 (dd, $J = 12, 8$ Hz, 1H), 2.69-2.74 (dd, $J = 12, 8$ Hz, 1H); $^{13}\text{C NMR}$ (100 MHz, $\text{D}_2\text{O}+\text{NaOH}$) δ 181.43, 154.44, 141.44, 136.69, 132.23, 125.89, 55.97, 55.76, 34.58; **HRMS-ESI** (m/z) $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_9\text{H}_{12}\text{N}_2\text{O}_3$: 197.0921; found, 197.0920.

(S)-2-amino-3-(3-methoxypyridin-4-yl) propanoic acid (3l)




White solid (55 mg, 56%); $^1\text{H NMR}$ (400 MHz, $\text{D}_2\text{O}+\text{NaOH}$) δ 7.94 (d, J = 4 Hz, 1H), 6.87 (d, J = 8 Hz, 1H), 6.68 (s, 1H), 3.83 (s, 3H), 3.59 (t, J = 8 Hz, 1H), 2.95-2.99 (dd, J = 12, 4 Hz, 1H), 2.81-2.86 (dd, J = 12, 8 Hz, 1H); $^{13}\text{C NMR}$ (100 MHz, $\text{D}_2\text{O}+\text{NaOH}$) δ 179.63, 163.91, 151.24, 146.17, 117.65, 110.48, 56.26, 53.99, 39.12; **HRMS-ESI** (m/z) $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_9\text{H}_{12}\text{N}_2\text{O}_3$: 197.0921; found, 197.0919.

(E)-3-(3-methylisoxazol-5-yl)acrylic acid (4a)




White solid (460mg, 66%) $^1\text{H NMR}$ (400 MHz, $\text{DMSO}-d_6$) δ 7.39 (d, J = 16 Hz, 1H), 6.74 (s, 1H), 6.66 (d, J = 16 Hz, 1H), 2.41 (s, 3H); $^{13}\text{C NMR}$ (100 MHz, $\text{D}_2\text{O}+\text{NaOH}$) δ 170.33, 166.55, 159.79, 130.77, 126.94, 99.88, 11.75; **HRMS-ESI** (m/z) $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_7\text{H}_7\text{NO}_3$: 154.0504; found, 154.0507.

(E)-3-(5-bromothiophen-2-yl)acrylic acid (4b)




White solid (265 mg, 57%) $^1\text{H NMR}$ (400 MHz, $\text{D}_2\text{O}+\text{NaOH}$) δ 7.33 (d, J = 16 Hz, 1H), 7.05 (d, J = 4 Hz, 1H), 7.00 (d, J = 4 Hz, 1H), 6.14 (d, J = 16 Hz, 1H); $^{13}\text{C NMR}$ (100 MHz, $\text{D}_2\text{O}+\text{NaOH}$) δ 175.12, 141.74, 132.94, 131.26, 130.32, 123.25, 113.78 ; **HRMS-ESI** (m/z) $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_7\text{H}_5\text{BrO}_2\text{S}$: 232.9272; found, 232.9265.

(E)-3-(4-bromothiophen-2-yl)acrylic acid (4c)




White solid (180 mg, 39%) $^1\text{H NMR}$ (400 MHz, $\text{D}_2\text{O}+\text{NaOH}$) δ 7.36 (s, 1H), 7.34 (d, J = 16 Hz, 1H), 7.18 (s, 1H), 6.25 (d, J = 16 Hz, 1H); $^{13}\text{C NMR}$ (100 MHz, $\text{D}_2\text{O}+\text{NaOH}$) δ 174.92, 140.97, 132.30, 131.11, 124.61, 124.08, 109.88; **HRMS-ESI** (m/z) $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_7\text{H}_5\text{BrO}_2\text{S}$: 232.9272; found, 232.9262.

(E)-3-(5-chlorothiophen-2-yl)acrylic acid (4d)




White solid (132 mg, 36%) $^1\text{H NMR}$ (400 MHz, $\text{D}_2\text{O}+\text{NaOH}$) δ 7.31 (d, $J = 16$ Hz, 1H), 7.03 (d, $J = 4$ Hz, 1H), 6.91 (d, $J = 4$ Hz, 1H), 6.11 (d, $J = 16$ Hz, 1H); $^{13}\text{C NMR}$ (100 MHz, $\text{D}_2\text{O}+\text{NaOH}$) δ 175.11, 138.92, 133.19, 130.99, 129.57, 127.52, 122.94; **HRMS-ESI** (m/z) $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_7\text{H}_5\text{ClO}_2\text{S}$: 188.9777; found, 188.9764.

(E)-3-(quinolin-4-yl)acrylic acid (4e)




White solid (257 mg, 65%) $^1\text{H NMR}$ (400 MHz, $\text{D}_2\text{O}+\text{NaOH}$) δ 8.19 (d, $J = 4$ Hz, 1H), 7.57 (t, $J = 8$ Hz, 2H), 7.48 (t, $J = 8$ Hz, 1H), 7.41 (d, $J = 16$ Hz, 1H), 7.31 (t, $J = 8$ Hz, 1H), 6.98 (d, $J = 4$ Hz, 1H), 6.22 (d, $J = 16$ Hz, 1H); $^{13}\text{C NMR}$ (100 MHz, $\text{D}_2\text{O}+\text{NaOH}$) δ 174.21, 148.79, 146.01, 141.09, 133.50, 130.53, 129.90, 127.41, 127.01, 125.19, 123.13, 117.38; **HRMS-ESI** (m/z) $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_{12}\text{H}_9\text{NO}_2$: 200.0712; found, 200.0736.

(E)-3-(isoquinolin-4-yl)acrylic acid (4f)




White solid (257 mg, 65%) $^1\text{H NMR}$ (400 MHz, $\text{D}_2\text{O}+\text{NaOH}$) δ 8.44 (s, 1H), 7.81 (s, 1H), 7.53 (d, $J = 8$ Hz, 1H), 7.41-7.48 (m, 2H), 7.28-7.37 (m, 2H), 6.04 (d, $J = 16$ Hz, 1H); $^{13}\text{C NMR}$ (100 MHz, $\text{D}_2\text{O}+\text{NaOH}$) δ 174.72, 151.68, 138.21, 133.66, 132.76, 131.44, 128.04, 127.72, 127.61, 127.13, 126.05, 121.92; **HRMS-ESI** (m/z) $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_{12}\text{H}_9\text{NO}_2$: 200.0712; found, 200.0735.

(S)-2-amino-3-(3-methylisoxazol-5-yl)propanoic acid (5a)




White solid (68 mg, 40%); $^1\text{H NMR}$ (400 MHz, $\text{D}_2\text{O}+\text{NaOH}$) δ 6.05 (s, 1H), 3.57-3.60 (dd, $J = 8, 4$ Hz, 1H), 2.96-3.01 (dd, $J = 12, 4$ Hz, 1H), 2.86-2.91 (dd, $J = 16, 8$ Hz, 1H), 2.35 (s, 3H); $^{13}\text{C NMR}$ (100 MHz, $\text{D}_2\text{O}+\text{NaOH}$) δ 180.08, 171.03, 161.68, 102.09, 54.66, 30.53, 11.32; **HRMS-ESI** (m/z) $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_7\text{H}_{10}\text{N}_2\text{O}_3$: 171.0770; found, 171.0751.


(S)-2-amino-3-(5-bromothiophen-2-yl)propanoic acid (5b)

 White solid (56 mg, 35%); ¹H NMR (400 MHz, D₂O+NaOH) δ 6.86 (d, *J* = 4 Hz, 1H), 6.57 (d, *J* = 4 Hz, 1H), 3.34 (t, *J* = 8 Hz, 1H), 2.96 (d, *J* = 8 Hz, 2H); ¹³C NMR (100 MHz, D₂O+NaOH) δ 181.53, 141.94, 130.07, 127.02, 109.38, 56.90, 35.16; HRMS-ESI (*m/z*) [*M*+H]⁺ Calcd for C₇H₈BrNO₂S: 249.9537; found, 249.9534.


(S)-2-amino-3-(4-bromothiophen-2-yl)propanoic acid (5c)

 White solid (90 mg, 54%); ¹H NMR (400 MHz, D₂O+NaOH) δ 7.13 (s, 1H), 6.75 (s, 1H), 3.36 (t, *J* = 8 Hz, 1H), 2.99 (d, *J* = 8 Hz, 2H); ¹³C NMR (100 MHz, D₂O+NaOH) δ 181.45, 141.69, 128.66, 122.02, 108.48, 56.97, 34.85; HRMS-ESI (*m/z*) [*M*+H]⁺ Calcd for C₇H₈BrNO₂S: 249.9537; found, 249.9537.



(S)-2-amino-3-(5-chlorothiophen-2-yl)propanoic acid (5d)


 White solid (87 mg, 44%); ¹H NMR (400 MHz, D₂O+NaOH) δ 6.82 (d, *J* = 4 Hz, 1H), 6.68 (d, *J* = 4 Hz, 1H), 3.52 (t, *J* = 4 Hz, 1H), 2.96 (d, *J* = 4 Hz, 2H); ¹³C NMR (100 MHz, D₂O+NaOH) δ 179.99, 138.32, 127.41, 126.31, 126.24, 56.63, 34.38; HRMS-ESI (*m/z*) [*M*+H]⁺ Calcd for C₇H₈ClNO₂S: 206.0043; found, 206.0047.



(S)-2-amino-3-(quinolin-4-yl)propanoic acid (5e)


 White solid (80 mg, 37%); ¹H NMR (400 MHz, D₂O+NaOH) δ 8.50 (d, *J* = 4 Hz, 1H), 8.00 (d, *J* = 8 Hz, 1H), 7.83 (d, *J* = 8 Hz, 1H), 7.63 (t, *J* = 8 Hz, 1H), 7.50 (t, *J* = 8 Hz, 1H), 7.18 (d, *J* = 4 Hz, 1H), 3.46-3.50 (dd, *J* = 8, 8 Hz, 1H), 3.25-3.30 (dd, *J* = 16, 8 Hz, 1H), 3.01-3.07 (dd, *J* = 16, 8 Hz, 1H); ¹³C NMR (100 MHz, D₂O+NaOH) δ 181.64, 149.51, 146.53, 146.24, 129.87, 127.97, 127.35, 126.89, 124.00, 122.36, 56.90, 37.33; HRMS-ESI (*m/z*) [*M*+H]⁺ Calcd for C₁₂H₁₂N₂O₂: 217.0977; found, 217.0973.



^1H NMR, ^{13}C NMR and HRMS spectra




















































































Spectrum Source
Peak (1) in "+ TIC Scan 5mo"

Fragmentor Voltage
175

Collision Energy
0

Ionization Mode
ESI








Spectrum Source
Peak (1) in "TIC Scan - Smo"

Fragmentor Voltage
175

Collision Energy
0

Ionization Mode
ESI








Spectrum Source
Peak (1) in "+ TIC Scan .smo"

Fragmentor Voltage
175

Collision Energy
0

Ionization Mode
ESI








Spectrum Source
Peak (1) in "+ TIC Scan Smo"


Fragmentor Voltage
175



Collision Energy
0


Ionization Mode
ESI









































































































































References

1. Lovelock, S. L.; Lloyd, R. C.; Turner, N. J. *Angew. Chem. Int. Ed.* **2014**, 53, 4652-4656.
2. Studier, F. W. *Prot. Expr. Purif.* **2005**, 41, 207-234.
3. Alexandre, F.-R.; Pantaleone, D. P.; Taylor, P. P.; Fotheringham, I. G.; Ager, D. J.; Turner, N. J. *Tetrahedron Lett.* **2002**, 43, 707-710.